Literature DB >> 33945791

Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.

Aimo Kannt1, Ivan Đikić2.   

Abstract

Efficacy and selectivity of molecules inducing protein degradation depend on their affinity to the target protein but also on the type of E3 ubiquitin ligase that is recruited to trigger proteasomal degradation. While tremendous progress has been made on the former, the latter-the arsenal of E3 ligases that can be hijacked for targeted protein degradation-is still largely unexplored. Only about 2% of the more than 600 E3 ligases have been utilized to date. Exploiting additional E3 ligases that are, for example, selectively expressed in specific tissues or cells, or regulated under certain conditions, can considerably broaden the applicability of molecular degraders as a therapeutic modality. Here, we provide an overview of major classes of E3 ligases, review the enzymes that have been exploited for induced protein degradation and approaches used to identify or design E3 ligands, and highlight challenges and opportunities for targeting new E3 ligases.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords:  E3 ubiquitin ligase; PROTAC; molecular glue; targeted protein degradation; ubiquitin-proteasome system

Year:  2021        PMID: 33945791     DOI: 10.1016/j.chembiol.2021.04.007

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  8 in total

1.  A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader.

Authors:  N Connor Payne; Semer Maksoud; Bakhos A Tannous; Ralph Mazitschek
Journal:  Cell Chem Biol       Date:  2022-05-31       Impact factor: 9.039

2.  Bifunctional Compounds as SMARCA2 Degraders for Treating Cancer.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-12-10       Impact factor: 4.345

3.  Ligandability of E3 Ligases for Targeted Protein Degradation Applications.

Authors:  Bridget P Belcher; Carl C Ward; Daniel K Nomura
Journal:  Biochemistry       Date:  2021-09-02       Impact factor: 3.162

Review 4.  Key Considerations in Targeted Protein Degradation Drug Discovery and Development.

Authors:  Liena Qin; Han Dai; Junfeng Wang
Journal:  Front Chem       Date:  2022-08-01       Impact factor: 5.545

Review 5.  Protein ubiquitination in T cell development.

Authors:  Ting Zhong; Kang Lei; Xiaoxi Lin; Zhiguo Xie; Shuoming Luo; Zhiguang Zhou; Bin Zhao; Xia Li
Journal:  Front Immunol       Date:  2022-08-04       Impact factor: 8.786

Review 6.  Targeting NRF2 to treat cancer.

Authors:  Jared Sivinski; Donna D Zhang; Eli Chapman
Journal:  Semin Cancer Biol       Date:  2021-06-05       Impact factor: 15.707

Review 7.  Fungal Secondary Metabolites as Inhibitors of the Ubiquitin-Proteasome System.

Authors:  Magdalena Staszczak
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

Review 8.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.